Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MC16
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa
Details : MC16 is unique in that it is designed to be a gene-mutation agnostic treatment with the potential to treat all forms of RP.
Product Name : MC16
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : MC16
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable